Drug intelligence / Profile preview

Ahah Drug

Development stage: Unknown
Lead developer: Trieu
Modality: Small Molecules
Administration: Oral

Overview

Ahah Drug is a plant-based herbal formulation developed by Dr. Nguyen Thi Trieu for the management of HIV/AIDS. The formulation consists of concentrated extracts from five plants: *Eclipta prostrata*, *Dioscorea cirrhosa*, *Phyllanthus urinaria*, *Adenosma glutinosum*, and *Impatiens balsamina*, combined with ascorbic acid (Vitamin C). It is intended to protect and increase the levels of CD4+ T lymphocytes and B lymphocytes in patients with HIV infection, thereby supporting the immune system and potentially reducing the impact of the virus. The drug has been evaluated in a Phase 4 randomized, double-blind, placebo-controlled trial to assess its efficacy in maintaining immune cell counts over a nine-month period.

Brand names: Ahah Drug
Other names: Ahah

Targets

CD4 (T lymphocyte surface antigen)

Beyond the preview

Go deeper on Ahah Drug.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ahah Drug.

Explore the full profile